NVAX vs NWSA · P/E 2.5, rev $196.2M vs rev $9.03B
Novavax Inc (NVAX) versus NWSA (NWSA) — a side-by-side from cached financials, not a winner call.
Novavax Inc (NVAX) is a biotechnology company listed on US.
NWSA (NWSA) common stock.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Latest reported NWSA revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 328.1% from 2025-06-30 to 2026-06-30. NWSA currently screens at market cap $0.
NVAX currently screens at market cap $1.09B and trailing P/E 2.5. NWSA currently screens at market cap $0.
Not investment advice. Open the NVAX and NWSA stock pages for the full models.
Not investment advice.